Loading...
Market
What will be Poseida's contribution to Roche's 2025 revenue growth?
3
Resolution / Starting Odds
Contributes more than 5% to revenue growth • 25%
Contributes 2-5% to revenue growth • 25%
Contributes less than 2% to revenue growth • 25%
No significant contribution • 25%
Roche's annual financial report for 2025
Story
Roche Completes $1.5 Billion Acquisition of Poseida Therapeutics, Securing 66% Stake by January 8
Jan 8, 2025, 12:15 PM
Roche Holdings AG has successfully completed its tender offer for Poseida Therapeutics, Inc., acquiring a 66% stake in the U.S. genetic engineering firm. The transaction, valued at approximately $1.5 billion, aims to enhance Roche's capabilities in developing new cancer treatments. The acquisition is set to finalize on January 8, 2025, following the completion of the tender offer, which saw significant participation from shareholders.
View original story
Similar markets
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$500 million to $1 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$1 billion to $2 billion • 25%
10% to 15% increase • 25%
Less than 5% increase • 25%
5% to 10% increase • 25%
More than 15% increase • 25%
13% - 15% • 25%
Above 18% • 25%
16% - 18% • 25%
10% - 12% • 25%
Increase by 20% to 30% • 25%
Increase by 10% to 20% • 25%
Increase by less than 10% • 25%
Increase by more than 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
Johnson & Johnson • 25%
Other • 25%
Roche • 25%
AstraZeneca • 25%
More than $3 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Top 100 • 25%
Below Top 200 • 25%
Top 200 • 25%
Top 50 • 25%
Increase between 10% and 20% • 25%
Increase by less than 10% • 25%
No significant increase • 25%
Increase by more than 20% • 25%